Obesity Drugmaker BioAge Seeks $158 Million in IPO, Placement
BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, is seeking to raise as much as $157.5 million in its initial public offering and a private placement.
Obesity drug developer BioAge seeks up to $587 mln valuation in US IPO
Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial public offering in the United States, according to a regulatory filing.
Obesity drugmaker BioAge targets $158 million in IPO
The company is offering 7.5 million shares for $17 to $19 apiece, according to a filing Wednesday
Drugmaker seeks $157.5M in IPO, placement
BioAge Labs, a clinical-stage biotech firm focused on obesity and metabolic disease therapies, aims to raise up to $157.5 million through its initial public offering and private placement, Bloomberg reported Sept. 18. The company plans to offer 7.5 million shares priced between $17 and $19 each, according to a filing with the Securities and Exchange Commission. At the top of the price range, BioAge's market valuation could reach $587 million. Previously, the company had a valuation of $394 million after raising $194 million in a Series D funding round in February.
Weight loss drug developer BioAge seeks up to $602M valuation in U.S. IPO
Obesity drug developer BioAge Labs (BIOA) files for U.S. IPO to offer 7.5M shares at $17-$19 implying valution of up to $602M. Read more here/
TAG24 NEWS on MSN12m
Obesity drug liraglutide helps children lose weight, study shows
Severe obesity is already a significant problem for many children, especially since obese children often become obese adults. Could the now popular weight-loss injection drugs be a solution for those ...
Impacts16h
Discover The Benefits Of Adding Obesity ETFs To Your Portfolio In 2024
Exchange-traded funds, commonly known as ETFs, are security baskets where a collection of investments is pooled. Like stocks, ...
Research That Led to Obesity Drugs Wins Major Medical Prize
Three scientists were recognized by the Lasker Awards for their work on the GLP-1 hormone. Others were honored for work to ...
EU regulator backs use of Novo's Wegovy for obesity-related heart condition
The European Medicines Agency backed the use of Novo Nordisk's popular drug Wegovy to help ease heart failure in people with ...
Child's Risk for Obesity Depends on Where Parents Can Shop for Food
The results jibe with earlier research showing that childhood obesity rates are steadily rising, even though food insecurity ...
Scientific American7h
Obesity-Drug Pioneers Win Prestigious Lasker Award for Medical Science
Three scientists are honored for developing a class of blockbuster weight-loss drugs. Is a Nobel prize on the way?
Are We Thinking About Obesity All Wrong?
It’s a brain disease,” a prominent obesity doctor explained on a “60 Minutes” episode about the drugs. “Obesity is disease” ...
Nature3d
Should young kids take the new anti-obesity drugs? What the research says
Evidence shows that blockbuster weight-loss medications can reduce obesity even in children aged 6–11, but their long-term ...
STAT17h
Corbus sees Novo’s controversial obesity approach as a ticket to a blockbuster
Why Corbus Pharmaceuticals sees Novo Nordisk’s controversial approach to obesity drugs as a ticket to a blockbuster.
Medical News Today2d
Even in obesity, regular exercise turns belly fat healthier
Research in people with obesity or overweight has shown that long-term exercisers have belly fat with healthier properties ...
federalnewsnetwork.com5h
How obesity in the armed services has become a national security problem
"When you have two-thirds plus of the active duty military force that's obese ... you know you've got a huge problem," ...